Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina (FAST AR)

Ferring

Status: Completed

Conditions: Advanced Hormone Dependent Prostate Cancer

Treatments: Drug: Firmagon® (degarelix)

Study type: Observational

Funder types: Industry

Identifiers

NCT01861236

000036

Details and patient eligibility

About

Prospective, observational study to collect and analyze data on patients with advanced hormone dependent prostate cancer treated with Firmagon® according to routine medical practice in Argentina

Enrollment: 90 patients

Sex: Male

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced Prostate Cancer patients to be treated with Firmagon in the context of usual clinical practice
• Written informed consent

Exclusion criteria

• Contraindications to Firmagon
• Patients already on Firmagon therapy

Trial design

90 participants in 1 patient group

Advanced Prostate Cancer

Description:

Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice

Treatment:

Drug: Firmagon® (degarelix)